However, there is a lack of consensus on whether individuals with F-HSCR and RET mutations should undergo surveillance for medullary thyroid carcinoma (MTC; OMIM#155240) or PHEO, particularly when MTC is absent. This evidence concerns the gene RET and medullary thyroid gland carcinoma.